Article
Prospective screening of novel antibacterial inhibitors of dihydrofolate reductase for mutational resistance.
Antimicrobial agents and chemotherapy - 1 Jul 2012
Frey Kathleen M, Viswanathan Kishore, Wright Dennis L, Anderson Amy C
Abstract excerpt
Resistance to trimethoprim (TMP) resulting from point mutations in the enzyme drug target dihydrofolate reductase (DHFR) drives the development of new antifolate inhibitors effective against methicillin-resistant Staphylococcus aureus (MRSA). For the past several years we have used structure-base...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
